Replies to post #15 on Immuron Limited (IMRN)

[Kauri]

If you are going to make statements you should read everything on the company.
Dilution was 10%. There are a total of 220mio equivalent ASX shares; This is all ASX ordinary shares, all ASX IMCOB options, all Nasdaq IMRN ADR's at 40:1 and all Nasdaq IMRNW warrants & the new issuance at 39 cents with attaching options.
So at USD$250mio market cap, or ~$1.45/$1.50 ASX or IMRN $45, then Immuron is an acceptable starting valuation. Even though Big pharma will likely pay USD$500mio-$1bio right now for the whole company, pipeline in Cdiff, NASH, ASH, travelan etc.
I am very happy with my ASX longs, ASX options & my IMRNW warrants.